Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Jaqueline Willemann-Rogerio | Researchclopedia

Back to researchers

Jaqueline Willemann-Rogerio

Merck & Co., Inc., Rahway, NJ, USA (United States)

6

Works

729

Citations

2

h-index

1

i10-index

Research Topics

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Bladder and Urothelial Cancer Treatments

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)2019–2021

Provincial Polyclinical Hospital in Toruń2021–2021

University College London2021–2021

Palacký University Olomouc2021–2021

Top Works

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri,Piotr Tomczak,et al.

2021725 citations

Pancreatic and Hepatic Oncology Research

Renal and related cancers

653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

Toni K. Choueiri,Piotr Tomczak,et al.

20213 citations

Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study

Toni K. Choueiri,David I. Quinn,et al.

20192 citations

Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors

Hans J. Hammers,Toni K. Choueiri,et al.

20210 citations

Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study

Toni K. Choueiri,David I. Quinn,et al.

20190 citations

PLLBA-01 PEMBROLIZUMAB (PEMBRO) VS PLACEBO AS POST NEPHRECTOMY ADJUVANT THERAPY FOR PATIENTS (pts) WITH RENAL CELL CARCINOMA (RCC): RANDOMIZED, DOUBLE-BLIND, PHASE 3 KEYNOTE-564 STUDY

Toni K. Choueiri,Piotr Tomczak,et al.

20210 citations